Patent: 5,196,320
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Summary for Patent: 5,196,320
| Title: | Method of producing engineered binding proteins |
| Abstract: | Disclosed are methods of producing fusion proteins including those with dual biological activities. These methods include the provision of a first and second DNA sequence encoding a first and second polypeptide, repectively, the digestion of the first DNA sequence at a restriction site adjacent its 3\' or 5\' terminus, and the ligation of a linker/adapter sequence (l/a) to the restricted end of the first DNA sequence, thereby forming a cassette. The l/a includes, at one end, that portion of the first DNA sequence extending from its terminus nearest the restriction site to the restriction site, and at the other end, one side of a splice site. A eucaryotic host cell is transfected with the cassette and the second DNA sequence having, at one end, one side of a splice site compatible with the side of the splice site on the l/a. The transfected host cell is cultured to express the transfected DNA as a single chain fusion protein. |
| Inventor(s): | Gillies; Stephen D. (Hingham, MA) |
| Assignee: | Abbott Biotech, Inc. (Needham Heights, MA) |
| Application Number: | 07/810,522 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,196,320
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Sign Up | 2010-03-23 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Sign Up | 2010-03-23 | |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Sign Up | 2010-03-23 | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
